Protein folding and cutaneous diseases

International Journal of Dermatology

Volumn 47, Issue 12, 2008, Pages 1225-1233

  Botelho, Michelle Gralle ^a,b,c   Lupi, Omar ^a,b,c  

^a MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c Instituto de Dermatologia Prof Rubem David Azulay   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; ANTIHISTAMINIC AGENT; BETA 2 MICROGLOBULIN; CALCIPOTRIOL; DIMETHYL SULFOXIDE; ETRETIN; ETRETINATE; HEMOGLOBIN; HUNTINGTIN; IMMUNOGLOBULIN LIGHT CHAIN; PREALBUMIN; STEROID;

AMINO ACID SEQUENCE; AMYLOIDOSIS; CELL DEATH; CEREBRAL AMYLOIDOSIS; DNA SEQUENCE; GENE MUTATION; HUMAN; INFECTION; MASS SPECTROMETRY; NONHUMAN; PATHOGENESIS; PHYSICAL EXAMINATION; PRION INFECTION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PRURITUS; REVIEW; SKIN BIOPSY; SKIN DISEASE;

AMYLOIDOSIS; ANIMALS; HUMANS; PRION DISEASES; PROTEIN CONFORMATION; PROTEIN FOLDING; SKIN DISEASES;

EID: 57049122396     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03851.x     Document Type: Review

References (56)

1. Anfinsen CB, Haber E, Sela M, et al. Kinetics of formation of native ribonuclease during oxidation of reduced polypeptide chain. Proc Natl Acad Sci USA 1961; 47: 1309-1314.
2. Levinthal C. Proceedings in Mössbauer Spectroscopy in Biological Systems. Urbana: University of Illinois Press, 1969: 22-24.
3. Hemmingsen SM, Woolford C, Vandervies SM, et al. Homologous plant and bacterial proteins chaperone oligomeric protein assembly. Nature 1988; 333: 330-334.
4. Bechtluft P, van Leeuwen RGH, Tyreman M, et al. Direct observation of chaperone-induced changes in a protein folding pathway. Science 2007; 318: 1458-1461.
5. Tanford C. Protein denaturation. Adv Protein Chem 1968; 23: 121-282.
6. Ikai A, Tanford C. Kinetic evidence for incorrectly folded intermediate states in the refolding of denatured proteins. Nature 1971; 230: 100-102.
7. True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 2000; 407: 477-483.
8. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 2006; 125: 443-451.
9. Gregersen N, Bross P, Andresen BS, et al. The role of chaperone-assisted folding and quality control in inborn errors of metabolism: Protein folding disorders. J Inherit Metab Dis 2001; 24: 189-212.
10. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from A β-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-6453.
11. Dickson DW, Crystal HA, Bevona C, et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16: 285-298.
12. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 4: 507-511.
13. Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci 2001; 24: 519-550.
14. Divry P, Florkin M. The optic properties of amyloid. C R Seances Soc Biol Fil 1927; 97: 1808-1810.
15. Vieira MN, Figueroa-Villar JD, Meirelles MN, et al. Small molecule inhibitors of lysozyme amyloid aggregation. Cell Biochem Biophys 2006; 44: 549-553.
16. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-1062.
17. Goate A, Chartierharlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
18. Norremolle A, Ries O, Epplen JT, et al. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet 1993; 2: 1475-1476.
19. Lee DD, Lin MW, Chen IC, et al. Genome-wide scan identifies a susceptibility locus for familial primary cutaneous amyloidosis on chromosome 5p13.1-q11.2. Br J Dermatol 2006; 155: 1201-1208.
20. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003; 81: 678-699.
21. Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22.
22. Perfetti V, Casarini S, Palladini G, et al. Analysis of V β-J β expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (βIII) as a new amyloid-associated germline gene segment. Blood 2002;100:948-953.
23. Kaplan B, Martin BM, Livneh A, et al. Biochemical subtyping of amyloid in formalin-fixed tissue samples confirms and supplements immunohistologic data. Am J Clin Pathol 2004; 121: 794-800.
24. Guidelines Working Group of UK Myeloma Forum; British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681-700.
25. Fujita Y, Tsuji-Abe Y, Sato-Matsumura KC, et al. Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis. J Am Acad Dermatol 2006; 54: 712-714.
26. Grunewald K, Sepp N, Weyrer K, et al. Gene rearrangement studies in the diagnosis of primary systemic and nodular primary localized cutaneous amyloidosis. J Invest Dermatol 1991; 97: 693-696.
27. Steciuk A, Dompmartin A, Troussard X, et al. Cutaneous amyloidosis and possible association with systemic amyloidosis. Int J Dermatol 2002; 41: 127-132.
28. Horiguchi Y, Suzuki S, Toda K, et al. Three-dimensional cultures of keratinocytes and an application to in vitro amyloid production of cutaneous amyloidosis. Microsc Res Tech 1997; 38: 38793.
29. Huilgol SC, Ramnarain N, Carrington P, et al. Cytokeratins in primary cutaneous amyloidosis. Australas J Dermatol 1998; 39: 81-85.
30. Wong CK, Lin CS. Friction amyloidosis. Int J Dermatol 1988; 27: 302-307.
31. Iwasaki J, Aki T, Yoshida Y, et al. "Thermie" and friction therapy performed using a special instrument. J Dermatol 2007; 34: 486-489.
32. Santos-Juanes J, Galache C, Curto JR, et al. Nodular primary localized cutaneous amyloidosis. J Eur Acad Dermatol Venereol 2004; 18: 224-226.
33. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: A long-term follow-up study. Br J Dermatol 2001; 145: 105-109.
34. Kalajian AH, Waldman M, Knable AL. Nodular primary localized cutaneous amyloidosis after trauma: A case report and discussion of the rate of progression to systemic amyloidosis. J Am Acad Dermatol 2007; 57: S26-S29.
35. Bozikov K, Janezic T. Excision and split thickness skin grafting in the treatment of nodular primary localized cutaneous amyloidosis. Eur J Dermatol 2006; 16: 315-316.
36. Khoo BP, Tay YK, Goh CL. Calcipotriol ointment vs. β-methasone 17-valerate ointment in the treatment of lichen amyloidosis. Int J Dermatol 1999; 38: 539-541.
37. Hernandez-Nunes A, Dauden E, de Vega MJM, et al. Widespread biphasic amyloidosis: Response to acitretin. Clin Exp Dermatol 2001; 26: 256-259.
38. Ozkaya-Bayazit E, Kavak A, Gungor H, et al. Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol 1998; 37: 949-954.
39. Pandhi R, Kaur I, Kumar B. Lack of effect of dimethylsulphoxide in cutaneous amyloidosis. J Dermatolog Treat 2002; 13: 11-14.
40. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-144.
41. Lupi O. Prions in dermatology. J Am Acad Dermatol 2002; 46: 790-793.
42. Lupi O. Could ectoparasites act as vectors for prion diseases? Int J Dermatol 2003; 42: 425-429.
43. Lupi O. Risk analysis of ectoparasites acting as vectors for chronic wasting disease. Med Hypotheses 2005; 65: 47-54.
44. Klatzo I, Gajdusek DC, Zigas V. Pathology of Kuru. Laboratory Invest 1959; 8: 799.
45. Gajdusek DC. Transmissible and nontransmissible dementas -Distinction between primary cause and pathogenetic mechanisms in Alzheimers-Disease and aging. Mt Sinai J Med 1988; 55: 3-5.
46. Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983; 35: 349-358.
47. Caughey BW, Dong A, Bhat KS, et al. Secondary structure-analysis of the scrapie-associated protein PRP 27-30 in water by infrared-spectroscopy. Biochemistry 1991; 30: 7672-7680.
48. Brown P, Liberski PP, Wolff A, et al. Conservation of infectivity in purified fibrillary extracts of scrapie-infected hamster brain after sequential enzymatic digestion or polyacrylamide-gel electrophoresis. Proc Natl Acad Sci USA 1990; 87: 7240-7244.
49. Mehlhorn I, Groth D, Stockel J, et al. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry 1996; 35: 5528-5537.
50. Riek R, Hornemann S, Wider G, et al. NMR structure of the mouse prion protein domain PrP (121-231). Nature 1996; 382: 180-182.
51. Lopez-Garcia F, Zahn R, Riek R, et al. NMR structure of the bovine prion protein. Proc Natl Acad Sci USA 2000; 97: 8334-8339.
52. Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic-criteria for Creutzfeldt-Jakob-Disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 1995; 5: 459-466.
53. Lupi O, Peryassu MA. An emerging concept of prion infections as a form of transmissible cerebral amyloidosis. Prion 2007; 1: 223-227.
54. Lundmark K, Westermark GT, Nystrom S, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 2002; 99: 6979-6984.
55. Lundmark K, Westermark GT, Olsen A, et al. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 2005; 102: 6098-6102.
56. Botelho MG, Azulay DR. Amiloidoses. Dermatologia. Rio de Janeiro: Guanabara Koogan, 2006: 456-458.